RT Journal Article
T1 Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2.
A1 Calina, Daniela
A1 Hernandez, Antonio F
A1 Hartung, Thomas
A1 Egorov, Alexey M
A1 Izotov, Boris Nikolaevich
A1 Nikolouzakis, Taxiarchis Konstantinos
A1 Tsatsakis, Aristidis
A1 Vlachoyiannopoulos, Panayiotis G
A1 Docea, Anca Oana
K1 COVID-19 pandemic
K1 coronaviruses
K1 mRNA vaccines
K1 public health
K1 side effects
AB In the context of the current COVID-19 pandemic, traditional, complex and lengthy methods of vaccine development and production would not have been able to ensure proper management of this global public health crisis. Hence, a number of technologies have been developed for obtaining a vaccine quickly and ensuring a large scale production, such as mRNA-based vaccine platforms. The use of mRNA is not a new concept in vaccine development but has leveraged on previous knowledge and technology. The great number of human resources and capital investements for mRNA vaccine development, along with the experience gained from previous studies on infectious diseases, allowed COVID-19 mRNA vaccines to be developed, conditionally approved and commercialy available in less than one year, thanks to decades of basic research. This review critically presents and discusses the COVID-19 mRNA vaccine-induced immunity, and it summarizes the most common anaphylactic and autoimmune adverse effects that have been identified until now after massive vaccination campaigns.
PB MDPI AG
SN 2075-1729
YR 2021
FD 2021-08-28
LK http://hdl.handle.net/10668/18569
UL http://hdl.handle.net/10668/18569
LA en
NO Calina D, Hernández AF, Hartung T, Egorov AM, Izotov BN, Nikolouzakis TK, et al. Challenges and Scientific Prospects of the Newest Generation of mRNA-Based Vaccines against SARS-CoV-2. Life (Basel). 2021 Aug 31;11(9):907.
DS RISalud
RD Apr 20, 2025